How many drugs treat Urge incontinence of urine?

Drug Landscape tracks 9 marketed treatments for Urge incontinence of urine (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/urge-incontinence-of-urine.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Urge incontinence of urine — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urge incontinence of urine (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Urge incontinence of urine, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Toviaz	Fesoterodine Fumarate	Pfizer	fesoterodine	Muscarinic acetylcholine receptor M2	2008-01-01
Toviaz	FESOTERODINE	Pfizer	fesoterodine	Muscarinic acetylcholine receptor M2	2008-01-01
Vesicare	SOLIFENACIN	Astellas Pharma	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	2004-01-01
Sanctura	TROSPIUM	AbbVie	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Enablex	DARIFENACIN	AbbVie	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Detrol	TOLTERODINE	Upjohn	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	1998-01-01
Ditropan Xl	OXYBUTYNIN	Hisamitsu Pharmaceutical Co., Inc.	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	1975-01-01
Oxytrol	Oxytrol	Jewish General Hospital		Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor
Vesicare	Vesicare	University of California, Irvine		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 2 drugs in Urge incontinence of urine
Pfizer · 2 drugs in Urge incontinence of urine
Hisamitsu Pharmaceutical Co., Inc. · 1 drug in Urge incontinence of urine
Jewish General Hospital · 1 drug in Urge incontinence of urine
University of California, Irvine · 1 drug in Urge incontinence of urine
· 1 drug in Urge incontinence of urine
Upjohn · 1 drug in Urge incontinence of urine
Astellas Pharma · 1 drug in Urge incontinence of urine

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Urge incontinence of urine:

Cite this brief

Drug Landscape (2026). Urge incontinence of urine — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/urge-incontinence-of-urine. Accessed 2026-06-10.

Urge incontinence of urine full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing